Skip Nav Destination
Article navigation
Editorial Views|
September 1994
Spinal Somatostatin for Patients with Cancer: Risk-Benefit Assessment of an Analgesic
Professor of Anesthesiology, Vice Chair for Research, Department of Anesthesiology, Anesthesia Research Laboratory, 0818 University of California, San Diego 9500 Gilman Drive, La Jolla, California 92093-0818
Anesthesiology September 1994, Vol. 81, 531–533.
Citation
Tony L. Yaksh; Spinal Somatostatin for Patients with Cancer: Risk-Benefit Assessment of an Analgesic. Anesthesiology 1994; 81:531–533 doi: https://doi.org/10.1097/00000542-199409000-00003
Download citation file:
Citing articles via
Most Viewed
Related Articles
Uterine Cervical Afferents in Thoracolumbar Dorsal Root Ganglia Express Transient Receptor Potential Vanilloid Type 1 Channel and Calcitonin Gene–related Peptide, but Not P2X3 Receptor and Somatostatin
Anesthesiology (April 2006)
Slick Potassium Channels Control Pain and Itch in Distinct Populations of Sensory and Spinal Neurons in Mice
Anesthesiology (May 2022)
Somatostatin Does Not Prevent Serotonin Release and Flushing during Chemoembolization of Carcinoid Liver Metastases
Anesthesiology (April 2003)
Association between Epidural Analgesia and Cancer Recurrence after Colorectal Cancer Surgery
Anesthesiology (July 2010)
Epidural Anesthesia–Analgesia and Recurrence-free Survival after Lung Cancer Surgery: A Randomized Trial
Anesthesiology (September 2021)
